Pediatric Drugs

, Volume 11, Issue 6, pp 375–380 | Cite as

Vasculitis in Children and Adolescents

Clinical Presentation, Etiopathogenesis, and Treatment
Review Article


The childhood vasculitides are a group of diseases affecting small to large blood vessels. The two most common conditions are Henoch-Schönlein purpura (HSP) and Kawasaki disease (KD). HSP is diagnosed on the basis of typical clinical findings and is mostly a self-limiting disease. KD is the most common vasculitis in infants and the development of coronary artery aneurysms is the major complication. Early treatment with intravenous immunoglobulin and aspirin (acetylsalicylic acid) is required to minimize this risk. All other vasculitides are very rare in children and include anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, polyarteritis nodosa and Takayasu disease.

The etiology of all these vasculitic diseases is generally unknown and, therefore, no specific treatment is available. The more rare vasculitides are generally much more severe, often needing treatment with high doses of corticosteroids and immunosuppressant agents such as cyclophosphamide, azathioprine, and mycophenolate mofetil.


Vasculitis Kawasaki Disease Mycophenolate Mofetil Takayasu Arteritis Polyarteritis Nodosa 



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Dillon MJ. Childhood vasculitis. Lupus 1998; 7(4): 259–65PubMedCrossRefGoogle Scholar
  2. 2.
    Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005 Feb; 98(2): 97–111PubMedCrossRefGoogle Scholar
  3. 3.
    Ozen S, Ruperte N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006 Jul; 65(7): 936–41PubMedCrossRefGoogle Scholar
  4. 4.
    Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994 Feb; 37(2): 187–92PubMedCrossRefGoogle Scholar
  5. 5.
    Lie JT. Nomenclature and classification of vasculitis: plus ca change, plus c’est la meme chose. Arthritis Rheum 1994 Feb; 37(2): 181–6PubMedCrossRefGoogle Scholar
  6. 6.
    Dillon MJ, Ozen S. A new international classification of childhood vasculitis. Pediatr Nephrol 2006 Sep; 21(9): 1219–22PubMedCrossRefGoogle Scholar
  7. 7.
    Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002 Oct 19; 360(9341): 1197–202PubMedCrossRefGoogle Scholar
  8. 8.
    Burns JC. Commentary: translation of Dr Tomisaku Kawasaki’s original report of fifty patients in 1967. Pediatr Infect Dis J 2002 Nov; 21(11): 993–5PubMedCrossRefGoogle Scholar
  9. 9.
    Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2001; 86: 286–90CrossRefGoogle Scholar
  10. 10.
    Brogan PA, Shah V, Clarke LA, et al. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol 2008 Feb; 151(2): 267–74PubMedCrossRefGoogle Scholar
  11. 11.
    Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003 Jun; 142(6): 611–6PubMedCrossRefGoogle Scholar
  12. 12.
    Rai A, Nast C, Adler S. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol 1999; 10: 2637–44PubMedGoogle Scholar
  13. 13.
    Tizard EJ. Henoch-Schonlein purpura. Arch Dis Child 1999; 80: 380–3PubMedCrossRefGoogle Scholar
  14. 14.
    Brogan PA. What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol 2007 Aug; 22(8): 1083–94PubMedCrossRefGoogle Scholar
  15. 15.
    Ronkainen J, Koskimies O, la-Houhala M, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006 Aug; 149(2): 241–7PubMedCrossRefGoogle Scholar
  16. 16.
    Dillon MJ. Henoch-Schonlein purpura: recent advances. Clin Exp Rheumatol 2007 Jan; 25 (1 Suppl. 44): S66–8PubMedGoogle Scholar
  17. 17.
    Kaku Y, Nohara K, Honda S. Renal involvement in Henoch-Schonlein purpura: a multivariate analysis of prognostic factors. Kidney Int 1998 Jun; 53(6): 1755–9PubMedCrossRefGoogle Scholar
  18. 18.
    Scharer K, Krmar R, Querfeld U, et al. Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol 1999 Nov; 13(9): 816–23PubMedCrossRefGoogle Scholar
  19. 19.
    Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr 2007 Feb; 166(2): 145–51PubMedCrossRefGoogle Scholar
  20. 20.
    Hogg RJ, Fitzgibbons L, Atkins C, et al. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol 2006 Nov; 1(6): 1167–72PubMedCrossRefGoogle Scholar
  21. 21.
    Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13: 1953–60PubMedCrossRefGoogle Scholar
  22. 22.
    Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 2004 Aug; 163(8): 425–34PubMedCrossRefGoogle Scholar
  23. 23.
    Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002 Sep; 17(9): 754–61PubMedCrossRefGoogle Scholar
  24. 24.
    Shovman O, Gilburd B, Zandman-Goddard G, et al. Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Curr Rheumatol Rep 2006 Aug; 8(4): 292–8PubMedCrossRefGoogle Scholar
  25. 25.
    Hogan SL, Cooper GS, Savitz DA, et al. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol 2007 Mar; 2(2): 290–9PubMedCrossRefGoogle Scholar
  26. 26.
    Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994 Jan; 120(1): 12–7PubMedGoogle Scholar
  27. 27.
    Ohtake T, Kobayashi S, Honjou Y, et al. Generalized Wegener’s granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. Intern Med 2001 Jul; 40(7): 666–70PubMedCrossRefGoogle Scholar
  28. 28.
    Brogan PA, Davies R, Gordon I, et al. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol 2002 Apr; 17(4): 277–83PubMedCrossRefGoogle Scholar
  29. 29.
    Bakkaloglu A, Ozen S. Wegener’s granulomatosis, microscopic polyangiitis and childhood polyarteritis nodosa. In: Geary DF, Schaeffer F, editors. Pediatric nephrology. Philadelphia (PA); Mosby Elsevier, 2008: 353–8Google Scholar
  30. 30.
    Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol 2002; 55: 481–6PubMedCrossRefGoogle Scholar
  31. 31.
    McCulloch M, Andronikou S, Goddard E, et al. Angiographic features of 26 children with Takayasu’s arteritis. Pediatr Radiol 2003 Apr; 33(4): 230–5PubMedGoogle Scholar
  32. 32.
    Millar AJ, Gilbert RD, Brown RA, et al. Abdominal aortic aneurysms in children. J Pediatr Surg 1996 Dec; 31(12): 1624–8PubMedCrossRefGoogle Scholar
  33. 33.
    Marks SD, Sebire NJ, Pilkington C, et al. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol 2007 Jan; 22(1): 77–83PubMedCrossRefGoogle Scholar
  34. 34.
    Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004 Feb; 15(2): 241–50PubMedCrossRefGoogle Scholar
  35. 35.
    Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004 Feb; 65(2): 521–30PubMedCrossRefGoogle Scholar
  36. 36.
    Steinlin MI, Blaser SI, Gilday DL, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995 Oct; 13(3): 191–7PubMedCrossRefGoogle Scholar
  37. 37.
    Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005 Oct; 52(10): 3168–74PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of Paediatric NephrologyGreat Ormond Street Hospital for Children NHS TrustLondonUK

Personalised recommendations